×

Biotech and Pharmaceuticals Pharmaceuticals

  • BOSTON, May 10- Billionaire investor William Ackman is making money on one of his new investment ideas, but he declined on Wednesday to identify the portfolio company, which has gained 30 percent since he first bought it. One makes up roughly 5 percent of Pershing Square Capital Management's $11 billion of capital and has gained about 30 percent, Ackman said.

  • Boxes of Eli Lilly & Co. Humalog medication sit on a pharmacy shelf in Provo, Utah.

    The increases fit a pattern of drugmakers making single-digit percentage hikes once or twice a year, despite political pressure.

  • Mylan President Rajiv Malik said the FDA was asking it to comply with standards set out in draft guidance the agency issued, but that it believes it is not required to do so. Malik said the company could not comment further on the length of the delay for approval until it meets with the FDA to discuss their disagreement, but that the FDA had designated it as requiring...

  • Mylan EpiPen

    EpiPen maker Mylan said on Wednesday first-quarter profit more than quadrupled, as the maker of generic drugs benefited from strong demand outside the U.S.

  • Mylan's affirmation of its 2017 forecast may be comforting to some following the U.S. Food and Drug Administration's recent rejection of the company's generic version of GlaxoSmithKline Plc's blockbuster Advair asthma treatment, Goldman Sachs analysts said. So far, Mylan has provided no details of the FDA's concerns or how long the product might be delayed.

  • Pharmacist Pharmacy medication

    The high cost of health care in the US is nothing compared to the markup on some prescription medicines. We reveal the most expensive drugs.

  • Mylan has come under fire for steep price increases for EpiPen, its life-saving allergy shot, and also for classifying the treatment as a generic rather than a branded product, leading to smaller rebates to state Medicaid programs. Mylan said net income surged to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents...

  • May 10- EpiPen maker Mylan NV said on Wednesday first-quarter profit more than quadrupled, as the maker of generic drugs benefited from strong demand outside the United States. The company said net income rose to $66.4 million, or 12 cents per share in the first quarter ended March 31, from $13.9 million, or 3 cents per share, a year earlier. Revenue rose to $2.69...

  • *Analysts say failure puts approval at risk. ZURICH, May 10- Roche's Tecentriq immuno-oncology drug failed a late-stage follow-up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine. Roche, the world's biggest maker of cancer drugs, had won...

  • ZURICH, May 10- Roche's Tecentriq drug has failed a late-stage trial in people with previously treated advanced bladder cancer, the Swiss drugmaker said on Wednesday, a setback in its plans to expand use of the immunotherapy. "While these results are not what we had expected, we believe that Tecentriq will continue to play an important role in the treatment of...

  • Cramer Remix: Where the money leaving retail stocks could be headed

    Jim Cramer pointed to consumer spending on vacations and travel as a possible pull from retail purchases.

  • Jim Cramer

    Jim Cramer pointed to consumer spending on vacations and travel as a possible pull from retail purchases.

  • Scott Gottlieb, a health policy expert and venture capitalist, as commissioner of the Food and Drug Administration, which regulates everything from food and drugs to tobacco, cosmetics and dietary supplements. The Senate voted 57-42 in favor of Gottlieb, a conservative physician and former deputy FDA commissioner under George W. Bush, who supporters say is...

  • Study: Expired Epipens may still be functional

    CNBC's Meg Tirrell reports on a study about Epipen's expiration dates.

  • Cut debt in first quarter: Valeant

    Tim Seymour, Triogem Asset Management, weighs in on his draft stock pick Valeant Pharmaceuticals.

  • May 9- Botox-maker Allergan Plc posted a first-quarter loss on Tuesday as it took a nearly $2 billion write-down on the value of its stake in Teva Pharmaceutical Industries, which has lost more than 40 percent of its value since last year. Allergan sold its generics business Actavis to Teva in August 2016 for $33 billion in cash and 100 million shares of the...

  • *Now sees 2017 adjusted EBITDA of $3.60- $3.75 bln. May 9- Canada's Valeant Pharmaceuticals International Inc raised its 2017 earnings forecast and reported its first profit in six quarters, helped by a one-time tax gain, and its U.S. shares jumped nearly 21 percent. Laval, Quebec- based Valeant said it expected 2017 earnings before interest, tax, depreciation and...

  • *Q1 adj. profit $1.23/ shr vs est $1.10/ shr. May 9- Endo International Plc reported a higher-than-expected quarterly adjusted profit, driven by strong demand for its newly launched generic drugs, sending its shares up more than 16 percent. Endo said total U.S. sales of generic drugs increased about 24 percent to $722 million in the first quarter ended March 31,...

  • The row is particularly fierce in the United States, where prices are higher than in Europe and where there have been highly publicised increases in some older products, such as Mylan's EpiPen for allergic reactions. "This complexity is undermining the reputation of an entire industry whose purpose is to make a positive change in patients lives," Sanofi Chief...

  • The row is particularly fierce in the United States, where prices are higher than in Europe. "This complexity is undermining the reputation of an entire industry whose purpose is to make a positive change in patients lives," Sanofi Chief Executive Olivier Brandicourt said in a statement on the group's website announcing the pricing policy.